Scarica l'app Stockscreener
0.00
100.00%
-7.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.87
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$594.49M
Reddito:
$83.57M
Utile/perdita netta:
$-4.94M
Rapporto P/E:
0.00
EPS:
-0.07
Flusso di cassa netto:
$6.97M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$9.18
Chromadex Corp Stock (CDXC) Company Profile
Nome
Chromadex Corp
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Confronta CDXC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDXC
Chromadex Corp
|
0.00 | 594.49M | 83.57M | -4.94M | 6.97M | -0.07 |
|
KHC
Kraft Heinz Co
|
29.60 | 35.99B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
56.14 | 31.49B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.77 | 28.46B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
74.60 | 20.20B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
29.88 | 16.82B | 11.92B | 805.04M | 1.01B | 1.46 |
Chromadex Corp Stock (CDXC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Chromadex Corp Borsa (CDXC) Ultime notizie
ChromaDex (NASDAQ:CDXC) Coverage Initiated by Analysts at StockNews.com - Defense World
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - MarketScreener
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments - MarketScreener
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - BioSpace
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com India
Niagen Bioscience maintains stability amid tariffs - Investing.com Australia
ChromaDex (NASDAQ:CDXC) Coverage Initiated at StockNews.com - Defense World
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Australia
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
Why ChromaDex Corp (CDXC) Is Surging In 2025? - Insider Monkey
Botanical Supplements Market In-depth Insights, Business - openPR.com
Why These 15 Defensive Stocks Are Surging In 2025 - Insider Monkey
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - Marketscreener.com
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com India
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors By Investing.com - Investing.com UK
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire Inc.
ChromaDex Corporation will Change its Name to Niagen Bioscience, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
ChromaDex’s (CDXC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients-USA.com
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - insights.citeline.com
ChromaDex to rebrand as Niagen Bioscience and change ticker By Investing.com - Investing.com Australia
Q1 Earnings Forecast for ChromaDex Issued By HC Wainwright - Defense World
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - BioSpace
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com India
Major Rebrand: ChromaDex Evolves to Niagen Bioscience, Sharpens Focus on Aging Science - StockTitan
ChromaDex to Present at the 37th Annual Roth Conference - BioSpace
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - StockTitan
ChromaDex (NASDAQ:CDXC) Given New $11.00 Price Target at HC Wainwright - Defense World
ChromaDex stock price target raised to $11 by H.C. Wainwright - Investing.com Australia
Chromadex corp. SVP buys $2,145 worth of common stock - Investing.com
ChromaDex Co. (NASDAQ:CDXC) Shares Bought by Rhumbline Advisers - Defense World
Truist Financial Corp Makes New $54,000 Investment in ChromaDex Co. (NASDAQ:CDXC) - Defense World
StockNews.com Downgrades ChromaDex (NASDAQ:CDXC) to Buy - Defense World
ChromaDex (NASDAQ:CDXC) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says - Defense World
Chromadex Corp Azioni (CDXC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Chromadex Corp Azioni (CDXC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
1.18%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):